S100A9: A potential biomarker for the progression of non-alcoholic fatty liver disease and the diagnosis of non-alcoholic steatohepatitis

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Liu, Xiaolin ^a   Wang, Yongfeng ^a   Ming, Yanan ^a   Song, Yanyan ^b   Zhang, Jingyi ^a   Chen, Xiaoyu ^a   Zeng, Minde ^a   Mao, Yimin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CALGRANULIN B; CHOLESTEROL; TRANSCRIPTION FACTOR T BET; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; GENE; GENE EXPRESSION; GIMAP4 GENE; GLUCOSE BLOOD LEVEL; HEPATITIS; HISTOPATHOLOGY; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; S100A9 GENE; SREBF1 GENE; TBX21 GENE; ANIMAL; METABOLISM;

RATTUS;

ANIMALS; BIOMARKERS; CALGRANULIN B; DISEASE PROGRESSION; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS;

EID: 84930628741     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127352     Document Type: Article

References (37)

1. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53: 372-384. doi: 10.1016/j.jhep.2010.04.008 PMID: 20494470
2. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55: 2005-2023. doi: 10.1002/hep.25762 PMID: 22488764
3. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011; 332: 1519-1523. doi: 10.1126/science.1204265 PMID: 21700865
4. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10: 330-344. doi: 10.1038/nrgastro.2013.41 PMID: 23507799
5. de Alwis NM and Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008; 48 Suppl 1: S104-112. doi: 10.1016/j.jhep.2008.01.009 PMID: 18304679
6. Abbas Z, Saeed A, Hassan SM, Luck NH, Khan A, Zafar MN, et al. Non-alcoholic fatty liver disease among visitors to a hepatitis awareness programme. Trop Gastroenterol. 2013; 34: 153-158. PMID: 24851524
7. Nishioji K, Sumida Y, Kamaguchi M, Mochizuki N, Kobayashi M, Nishimura T, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population. J Gastroenterol. 2015; 50:95-108 doi: 10.1007/s00535-014-0948-9 PMID: 24619537
8. Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol. 2012; 27: 1555-1560. doi: 10.1111/j.1440-1746.2012.07222.x PMID: 22741595
9. Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol. 2014; 20: 14205-14218. doi: 10.3748/wjg.v20.i39.14205 PMID: 25339807
10. Tziomalos K, Athyros VG, Karagiannis A. Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Curr Vasc Pharmacol. 2012; 10: 162-172. PMID: 22239625
11. Sumida Y, Eguchi Y, Ono M. Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan. World J Hepatol. 2010; 2: 374-383. doi: 10.4254/wjh.v2.i10.374 PMID: 21160946
12. Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014; 20: 475-485. doi: 10.3748/wjg.v20.i2.475 PMID: 24574716
13. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013; 58: 1007-1019. doi: 10.1016/j.jhep.2012.11.021 PMID: 23183525
14. Xu ZJ, Fan JG, Ding XD, Qiao L, Wang GL. Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Dig Dis Sci. 2010; 55: 931-940. doi: 10.1007/s10620-009-0815-3 PMID: 19459046
15. Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol. 2008; 23: 1635-1648. doi: 10.1111/j.1440-1746.2008.05543.x PMID: 18752564
16. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res. 2005; 52: 313-320. PMID: 15979893
17. Qiang G, Zhang L, Yang X, Xuan Q, Shi L, Zhang H, et al. Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes. Eur J Pharmacol. 2012; 685: 156-164. doi: 10.1016/j.ejphar.2012.04.028 PMID: 22546234
18. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41: 1313-1321. PMID: 15915461
19. Hou L, Lian K, Yao M, Shi Y, Lu X, Fang L, et al. Reduction of n-3 PUFAs, specifically DHA and EPA, and enhancement of peroxisomal beta-oxidation in type 2 diabetic rat heart. Cardiovasc Diabetol. 2012; 11: 126. doi: 10.1186/1475-2840-11-126 PMID: 23057715
20. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014; 59: 1174-1197. doi: 10.1002/hep.26717 PMID: 24002776
21. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol. 2012; 18: 727-735. doi: 10.3748/wjg.v18.i8.727 PMID: 22371632
22. Averill MM, Barnhart S, Becker L, Li X, Heinecke JW, Leboeuf RC, et al. S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells: implications for atherosclerosis and adipose tissue inflammation. Circulation. 2011; 123: 1216-1226. doi: 10.1161/CIRCULATIONAHA.110.985523 PMID: 21382888
23. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007; 13: 1042-1049. PMID: 17767165
24. Taccioli C, Wan SG, Liu CG, Alder H, Volinia S, Farber JL, et al. Zinc replenishment reverses overexpression of the proinflammatory mediator S100A8 and esophageal preneoplasia in the rat. Gastroenterology. 2009; 136: 953-966. doi: 10.1053/j.gastro.2008.11.039 PMID: 19111725
25. Agra RM, Fernandez-Trasancos A, Sierra J, Gonzalez-Juanatey JR, Eiras S. Differential association of S100A9, an inflammatory marker, and p53, a cell cycle marker, expression with epicardial adipocyte size in patients with cardiovascular disease. Inflammation. 2014; 37: 1504-1512. doi: 10.1007/s10753-014-9876-3 PMID: 24700313
26. Sekimoto R, Kishida K, Nakatsuji H, Nakagawa T, Funahashi T, Shimomura I. High circulating levels of S100A8/A9 complex (calprotectin) in male Japanese with abdominal adiposity and dysregulated expression of S100A8 and S100A9 in adipose tissues of obese mice. Biochem Biophys Res Commun. 2012; 419: 782-789. doi: 10.1016/j.bbrc.2012.02.102 PMID: 22390934
27. Bouma G, Lam-Tse WK, Wierenga-Wolf AF, Drexhage HA, Versnel MA. Increased serum levels of MRP-8/14 in type 1 diabetes induce an increased expression of CD11b and an enhanced adhesion of circulating monocytes to fibronectin. Diabetes. 2004; 53: 1979-1986. PMID: 15277376
28. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012; 55: 77-85. doi: 10.1002/hep.24706 PMID: 21953442
29. Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int. 2009; 29: 1431-1438. doi: 10.1111/j.1478-3231.2009.02022.x PMID: 19422483
30. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009; 50: 1072-1078. doi: 10.1002/hep.23050 PMID: 19585618
31. Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014; 60: 167-174. doi: 10.1016/j.jhep.2013.07.042 PMID: 23973932
32. Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, et al. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology. 2013; 57: 103-111. doi: 10.1002/hep.26030 PMID: 22930399
33. Liu JX, Liu J, Li PQ, Xie XD, Guo Q, Tian LM, et al. Association of sterol regulatory element-binding protein-1c gene polymorphism with type 2 diabetes mellitus, insulin resistance and blood lipid levels in Chinese population. Diabetes Res Clin Pract. 2008; 82: 42-47. doi: 10.1016/j.diabres.2008.06.017 PMID: 18692268
34. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 2009; 116: 539-564. doi: 10.1042/CS20080253 PMID: 19243311
35. Chen S, Zhao W, Tan W, Luo X, Dan Y, You Z, et al. Association of TBX21 promoter polymorphisms with type 1 autoimmune hepatitis in a Chinese population. Hum Immunol. 2011; 72: 69-73. doi: 10.1016/j.humimm.2010.10.019 PMID: 20977921
36. Filen JJ, Filen S, Moulder R, Tuomela S, Ahlfors H, West A, et al. Quantitative proteomics reveals GIMAP family proteins 1 and 4 to be differentially regulated during human T helper cell differentiation. Mol Cell Proteomics. 2009; 8: 32-44. doi: 10.1074/mcp.M800139-MCP200 PMID: 18701445
37. Davila S, Froeling FE, Tan A, Bonnard C, Boland GJ, Snippe H, et al. New genetic associations detected in a host response study to hepatitis B vaccine. Genes Immun. 2010; 11: 232-238. doi: 10.1038/gene.2010.1 PMID: 20237496